Positive results for “wonder” cancer treatment

I reported previously (Dec 2013) that VB-111 from Israel’s Vascular Biogenics (VBL Therapeutics) had been fast-tracked by the US FDA for the treatment of GBM – aggressive brain cancer.  Meanwhile, VBL has announced that VB-111’s Phase 2 trial for thyroid cancer was successful.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *